Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. director John W. Childs reported a grant of stock options covering 68,693 Common Shares. The options have an exercise price of $9.61 per share, expire on April 28, 2036, and were received as a compensation award rather than an open‑market purchase.
These options will vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, provided Childs continues serving the company through that date. Following this grant, he holds 68,693 stock options directly.
Biohaven Ltd. director Robert J. Hugin received a grant of stock options, giving him the right to buy 68,693 common shares at an exercise price of $9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to his continuous service. After this award, he holds 68,693 stock options directly, with an expiration date of April 28, 2036.
Biohaven Ltd. director Julia P. Gregory received a grant of 68,693 stock options to buy Common Shares at an exercise price of $9.61 per share. The options expire on April 28, 2036 and represent compensation rather than an open-market purchase.
These options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided she continues serving the company through that vesting date. After this award, she holds 68,693 stock options directly.
Biohaven Ltd. director Kishan Mehta reported bona fide gift transfers of a total of 34,684 common shares on 2026-03-17. One transfer of 17,342 shares reduced his directly held stake to 5,320 common shares.
A separate 17,342-share transfer is shown as indirectly held by the “Kishen Mehta 21 Family Irrevocable Trust.” The trust is for the benefit of family members other than the reporting person, and Mehta disclaims beneficial ownership of the securities held by the trust.
Biohaven Ltd. is asking shareholders to approve three items at its 2026 annual meeting: elect three directors to serve until 2029, ratify Ernst & Young LLP as auditor for 2026, and approve on an advisory basis executive compensation.
The proxy highlights 2025 R&D progress, including extracellular protein degrader programs in IgA nephropathy and Graves’ disease, an epilepsy candidate opakalim with seizure reduction data, and obesity drug taldefgrobep entering Phase 2. Oncology antibody–drug conjugate programs and several discovery-stage assets are also described.
The board has eight members, six deemed independent, with a combined chair/CEO and a lead independent director. As of March 3, 2026, 150,420,584 common shares were outstanding; two institutional holders each own more than 5%. The company emphasizes financial discipline, equity ownership guidelines, and standard NYSE-aligned governance practices.
Biohaven Ltd. director John W. Childs reported an amended insider transaction showing an indirect open‑market purchase of 28,400 Common Shares by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share.
The amendment corrects an earlier filing that had allocated 3,400 purchased shares to a 2013 Charitable Remainder Trust and 25,000 shares to the revocable trust. It clarifies that all 28,400 shares were acquired through the revocable trust, with no shares acquired through the charitable remainder trust in this transaction.
Biohaven Ltd. Chief Financial Officer Matthew Buten reported an award of stock options on a Form 4. He acquired 175,000 stock options as a grant, bringing his directly owned derivative holdings in this award to 175,000 options. The options vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, as long as he continues serving the company on each vesting date. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Gentile Kimberly reported acquisition or exercise transactions in this Form 4 filing.
Biohaven Ltd. reported that senior vice president of clinical operations Kimberly Gentile received a grant of stock options covering 175,000 shares. The options were awarded on February 27, 2026 and will vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, conditioned on her continuous service with the company.
Biohaven Ltd. reported that its VP and Chief Accounting Officer, Clark George C., received a grant of stock options covering 50,000 shares of the company’s stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
The options vest in four equal installments on February 27 of each year from 2026 through 2029, and each vesting tranche requires Clark George C. to remain continuously employed by Biohaven through the relevant vesting date.
Biohaven Ltd. Chief Scientific Officer Bruce Car received a grant of stock options on February 27, 2026. The award covers 175,000 stock options with an exercise price of $0.00 per share, giving him the right to buy Biohaven shares if he chooses to exercise in the future.
The options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each installment requires his continuous service with the company through the relevant vesting date. After this grant, he directly holds 175,000 derivative securities in the form of stock options.